General Gastro News Articles
Gastro
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Gastro
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Gastro
        Basic Science/Genetics
        Biliary System/Pancreas
        Colorectal Cancer/Polyps
        Economics of Medicine
        Endoscopy
        Esophagus
        GERD/Stomach
        GI Bleeding
        GI Infectious Disease
        GI Motility
        GI Oncology
        Hepatology
        Inflammatory Bowel Dz
        Obesity
        Parenteral/Ent Nutrition
        Peds Gastroenterology
        Pharmacology/kinetics
        Popular Press
        Radiology/Diagnostics
        Small/Large Intestine
        Transplant
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Top Ten Searches
esophageal  esophageal
probiotics  probiotics
bile duct  bile duct
hepatotoxicity  hepatotoxicity
dyspepsia  dyspepsia
colonoscopy  colonoscopy
helicobacter  helicobacter
hemochromatosis  hemochromatosis
colitis  colitis
resection  resection
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases – A 10-year study
Karanjia ND et al. - In a study to assess the outcome of colorectal liver metastases (CRLM) treated by a combination of neo-adjuvant chemotherapy and surgery, it was determined that neo-adjuvant chemotherapy followed by liver surgery is associated with improved survival and low CIRM and re-resection rates.

Methods
  • 283 consecutive pts underwent liver resection for CRLM over 10 yrs with curative intent.
  • Pts received chemotherapy preoperatively for synchronous and early (<2 yrs) metachronous metastases.
  • Univariate and multivariate analyses were used to identify mortality risk factors.

Results
  • Overall survival (OS) at 1, 3, and 5 yrs was 90%, 59.2% and 46.1%, respectively.
  • Disease free survival at 1, 3, and 5 yrs was 68.1%, 34.8%, and 27.9%, respectively.
  • Operative mortality was 2.1% and morbidity was 23.7%.
  • Pts with macroscopic diaphragm invasion by tumour, CEA >100 ng/ml, tumour size >5 cm or cancer involved resection margins (CIRM) had a significantly worse OS.
  • Incidence of CIRM and re-resection was 4.9% and 4.5%, respectively.
[more...]
Sponsor

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Gastroenterology Profession Index

Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.